Tran Cao Hop S, Zhang Qianzi, Sada Yvonne H, Chai Christy, Curley Steven A, Massarweh Nader N
Michael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, Texas.
Department of Medicine, Baylor College of Medicine, Houston, Texas.
Cancer. 2018 Jan 1;124(1):74-83. doi: 10.1002/cncr.30968. Epub 2017 Aug 25.
Lymph node metastasis is a poor prognostic factor for biliary tract cancers (BTCs). The optimal management of patients who have BTC with positive regional lymph nodes, including the impact of surgery and adjuvant therapy (AT), is unclear.
This was a retrospective cohort study of patients who had T1-T3N1M0 gallbladder cancer (GBC) and intrahepatic cholangiocarcinoma (IHC) in the National Cancer Database (2004-2012). Patients were classified by treatment approach (nonoperative, surgery, surgery plus AT). Associations between the overall risk of death and treatment strategy were evaluated with multivariable Cox regression.
Rates of surgical resection were 84.1% for patients with GBC (n = 1335) and 36.6% for those with IHC (n = 1009). The median overall survival of patients in the nonoperative, surgery, and surgery plus AT group was 11.6, 13.3, and 19.6 months, respectively, for those with GBC (log-rank P < .001), and 12.7, 16.2, and 22.6 months, respectively, for those with IHC (log-rank P < .001), respectively. Compared with nonoperative therapy, surgery with or without AT was associated with a lower risk of death from GBC (surgery with AT: hazard ratio [HR], 0.59; 95% confidence interval [CI], 0.48-0.73; surgery without AT: HR, 0.71; 95% CI, 0.56-0.89) and from IHC (surgery with AT: HR, 0.52; 95% CI, 0.42-0.63; surgery without AT: HR, 0.70; 95% CI, 0.56-0.87). AT that included radiation was associated with a lower risk of death relative to surgery alone for patients with GBC regardless of margin status (margin-negative resection: HR, 0.66; 95% CI, 0.52-0.84; margin-positive resection: HR, 0.54; 95% CI, 0.39-0.75), but adjuvant chemotherapy alone was not. For patients with IHC, no survival benefit was detected with adjuvant chemotherapy or radiation for those who underwent either margin-positive or margin-negative resection.
The best outcomes for patients who have lymph node-positive BTCs are associated with margin-negative resection and, in those who have GBC, the inclusion of adjuvant chemotherapy with radiation regardless of margin status. Cancer 2018;124:74-83. © 2017 American Cancer Society.
淋巴结转移是胆道癌(BTC)预后不良的因素。对于区域淋巴结阳性的BTC患者,包括手术和辅助治疗(AT)的影响在内的最佳治疗方案尚不清楚。
这是一项对国家癌症数据库(2004 - 2012年)中T1 - T3N1M0胆囊癌(GBC)和肝内胆管癌(IHC)患者的回顾性队列研究。患者按治疗方法(非手术、手术、手术加AT)分类。采用多变量Cox回归评估总死亡风险与治疗策略之间的关联。
GBC患者(n = 1335)的手术切除率为84.1%,IHC患者(n = 1009)的手术切除率为36.6%。GBC患者中,非手术组、手术组和手术加AT组的中位总生存期分别为11.6个月、13.3个月和19.6个月(对数秩检验P <.001);IHC患者中,相应的中位总生存期分别为12.7个月、16.2个月和22.6个月(对数秩检验P <.001)。与非手术治疗相比,无论是否进行AT,手术治疗GBC(手术加AT:风险比[HR],0.59;95%置信区间[CI],0.48 - 0.73;未行AT的手术:HR,0.71;95% CI,0.56 - 0.89)和IHC(手术加AT:HR,0.52;95% CI,0.42 - 0.63;未行AT的手术:HR,0.70;95% CI,0.56 - 0.87)的死亡风险均较低。对于GBC患者,无论切缘状态如何,包含放疗的AT与单纯手术相比死亡风险较低(切缘阴性切除:HR,0.66;95% CI,0.52 - 0.84;切缘阳性切除:HR,0.54;95% CI:0.39 - 0.75),但单纯辅助化疗则不然。对于IHC患者,无论切缘阳性或阴性切除,辅助化疗或放疗均未检测到生存获益。
区域淋巴结阳性的BTC患者的最佳治疗结果与切缘阴性切除相关,对于GBC患者,无论切缘状态如何,均应包含辅助化疗和放疗。《癌症》2018年;124:74 - 83。© 2017美国癌症协会